14.07.2025
Wedel, Germany 14 July 2025 – With over 25 years of aseptic manufacturing experience, medac CDMO enters the global CDMO market under a single, unified brand in 2025. This strategic rebranding brings together two GMP-certified production sites in Germany and the Czech Republic alongside the headquarters in Wedel, aligning capabilities, management and mission. Under the new claim a solution ahead medac positions its CDMO business as a proactive, agile partner for sterile manufacturing – committed to long-term customer partnerships and accelerated time-to-market.
In July 2025, the contract development and manufacturing operations of medac take a bold step forward: the launch of medac CDMO (Contract Development and Manufacturing Organisation). What once operated as separate entities across two production sites in Germany and the Czech Republic, together with the headquarters in Wedel is now united under one clear brand and one common vision. This strategic consolidation marks the beginning of a new chapter, reinforcing medac CDMO’s commitment to excellence, customer-centricity and innovation in sterile pharmaceutical manufacturing.
To accompany this transformation, medac CDMO has launched its new website www.medac-CDMO.com offering insights into its capabilities, expertise and services tailored to the needs of global pharmaceutical partners.
With more than 25 years of proven expertise in aseptic processing of pre-filled syringes and vials, medac CDMO offers end-to-end solutions – from clinical supply to commercial-scale production. The relaunch of medac CDMO brings together two GMP-certified sites in the heart of Europe under one centralised management system. This integration enhances agility, efficiency and scalability, while creating internal back-up capabilities and synergies that deliver greater flexibility, reliability and faster time-to-market for clients.
medac CDMO - a solution ahead
At the core of this transformation lies the new brand claim: a solution ahead. It reflects medac CDMO’s proactive mindset and dedication to staying ahead of industry demands. From managing complex regulatory challenges to implementing cutting-edge technologies, the company is structured to go beyond standard solutions.
“We see this unification not just as a rebranding, but as a renewal of our promise to customers,” said Gerhard Wurzer, COO of medac. “With our forward-thinking approach, robust infrastructure, and deep commitment to quality, medac CDMO is set to become a trusted partner in sterile manufacturing – particularly for complex dosage forms and both small and large molecule drugs.”
Built for Long-Term Partnerships
The site integration also strengthens the long-standing philosophy of building enduring partnerships. The company’s operating model is rooted in transparent communication, flexible production planning and dedicated project teams – ensuring alignment with customer goals. Additionally, medac is investing in employer branding to attract top talent in pharmaceutical science and manufacturing.
Looking Ahead
With a unified brand, a clear vision and expanded capabilities, medac CDMO is ready to take on a greater role in the global CDMO landscape. The company will showcase its enhanced offering at key industry events, including CPHI 2025 in Frankfurt, where it aims to highlight its commitment to quality, reliability, customer satisfaction and global outreach.
“Bringing our CDMO activities together under one name allows us to better serve our customers – and better shape the future of sterile manufacturing”, Wurzer concluded.